Alembic Pharmaceuticals received USFDA approval for Carbidopa, Levodopa and Entacapone tablets, which is indicated for the treatment of Parkinson’s disease. Q3 revenue rose 10.8% but net profit fell 4.1%.
Alembic Pharmaceuticals received USFDA approval for Carbidopa, Levodopa and Entacapone tablets, which is indicated for the treatment of Parkinson’s disease. Q3 revenue rose 10.8% but net profit fell 4.1%.